Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BMS-986340 + Docetaxel |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BMS-986340 | BMS 986340|BMS986340 | CCR8 Antibody 9 | BMS-986340 is a nonfucosylated monoclonal antibody that targets CCR8, with potential antitumor activity and ability to enhance antitumor immune response (Cancer Res 2020;80(16 Suppl):Abstract nr 6694). | |
Docetaxel | Taxotere | RP56976 | Antimicrotubule Agent 14 | Taxotere (docetaxel) binds to tubulin, inhibiting microtubule disassembly and preventing cell division (PMID: 32496783, PMID: 32366558). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04895709 | Phase Ib/II | BMS-986340 + Docetaxel BMS-986340 BMS-986340 + Nivolumab | A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors | Recruiting | USA | ITA | ISR | ESP | DEU | CAN | AUS | 1 |